Quantum BioPharma Raises C$3.75 Million and Converts Debt in Capital Restructuring Push

Quantum Biopharma ( (TSE:QNTM) ) has issued an update.

Quantum BioPharma has closed the first tranche of a previously announced private placement, issuing 3,750 debenture units for proceeds of C$3.75 million to support the development of its business model and to fund general working capital. The financing included a C$300,000 subscription by a company director, which qualified as a related-party transaction but fell below the thresholds requiring a formal valuation or minority shareholder approval under Canadian securities rules.

The company also completed an initial segment of a debt settlement by issuing 370,457 Class B subordinate voting shares to retire about C$1.12 million in obligations owed to a mix of arm’s-length creditors and insiders. That share-based debt conversion, which similarly constituted a related-party transaction, is expected to improve Quantum BioPharma’s balance sheet while modestly diluting existing shareholders, and was expedited without a prior material change report in order to accelerate the company’s capital restructuring.

More about Quantum Biopharma

Quantum BioPharma Ltd. is a biopharmaceutical company developing a portfolio of innovative assets and biotech solutions targeting neurodegenerative and metabolic disorders as well as alcohol misuse. Through its wholly owned subsidiary Lucid Psycheceuticals Inc., the company is advancing Lucid-MS, a patented new chemical entity that has shown an ability in preclinical models to prevent and reverse myelin degradation, the underlying mechanism of multiple sclerosis. Quantum BioPharma also invented the alcohol-related product UNBUZZD and spun out its over-the-counter version to Celly Nutrition Corp., in which it retains a minority equity stake and a royalty interest on future sales.

Average Trading Volume: 9,146

Technical Sentiment Signal: Sell

Current Market Cap: C$12.81M

See more insights into QNTM stock on TipRanks’ Stock Analysis page.